Pfizer Inc. (PFE) — Fair Value Analysis

Base-case fair value (P50): $22.18 · Current price: $24.32 · Verdict: Fairly Valued

The Verdict on PFE

Monte Carlo simulations suggest Pfizer (PFE) is currently Fairly Valued, with its $24.32 trading near our median fair value (P50) of $22.18. This assessment indicates that while there's a slight -8.8% difference from the current market price to the P50, it falls within the range considered fair by our probabilistic models. Investors weighing PFE should note this equilibrium, as the simulations account for thousands of potential future scenarios, anchoring the fair value close to where the stock currently trades.

How PFE stacks up against Healthcare

Despite being Fairly Valued by our Monte Carlo analysis, Pfizer's operational and financial health is categorized as "weak" compared to its peers within the Healthcare sector. This "weak" quality tier suggests that while the stock price of $24.32 aligns with the intrinsic value of $22.18, the company’s underlying fundamentals relative to its industry might present a constrained environment for significant organic re-rating. The assessment considers factors that could influence PFE's future performance, tempering expectations for substantial outperformance from its current valuation.

What this means for investors

For investors, the Fairly Valued verdict on PFE, coupled with its "weak" quality tier, implies that the current price of $24.32 accurately reflects its intrinsic value, with our P50 estimate at $22.18. The modest -8.8% indicates limited near-term catalyst potential solely based on valuation arbitrage. FairCurve’s Monte Carlo simulations provide a robust probabilistic framework for this assessment. To understand the full spectrum of outcomes, including distinct bear and bull case scenarios and the probability distribution around PFE’s fair value, sign up for a free FairCurve account.